Novel therapy interrupting the CXCR4-CXCL12 axis may weaken the protective role of the bone marrow microenvironment, enhance the sensibility of CML cells to TKI, and even eliminate LSC. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.